Aurélie Grienenberger

Aurélie Grienenberger has worked in a variety of roles since 1997. Aurélie began their career as a PhD Student at IBDM in 1997. Aurélie then moved on to Voisin Consulting in 2001 as a Senior Consultant. In 2004, they joined Dyax Corp. as a Director of Regulatory Affairs and later as an Associate Director of Regulatory Affairs. From 2010 to 2013, they worked at Fovea Pharmaceuticals as a Global Project Leader. Her most recent role was at Sanofi, where they served as Director of Transactions - Global Licensing & Business Development and Head of Office, President Global R&D from 2013 to 2019. Currently, they are the Chief Business Officer at Eligo Bioscience.

Aurélie Grienenberger's education history includes a Business Master from London Business School in 2012, an MS in Statistics Applied to Clinical Research from CESAM in 2002, a PhD in Genetics/Cell Biology from the University of Marseille/IBDM between 1996 and 2001, an MS in Maths, Physics, Chemistry, and Biology from École Polytechnique between 1993 and 1996, and a baccalaureat from Lycee Kleber between 1988 and 1991.